三生国健双抗新药授权辉瑞;华神科技收到四川证监局行政监管措施决定书|医药早参

每日经济新闻
21 May

|2025年5月21日星期三|  NO.1 三生国健双抗新药授权辉瑞  科创板创新药企业三生国健宣布,公司及关联方三生制药和沈阳三生制药有限责任公司共同授予辉瑞PD-1/VEGF双特异性抗体SSGJ-707在全球(不包括中国内地)的独家开发、生产、商业化权利。据悉,辉瑞将支付12.5亿美元不可退还且不可抵扣的首付款,最高可达48亿美元的开发、监管批准和销售里程碑付款,以及根据授权地区产品销售额计算...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10